[HTML][HTML] The development of COVID-19 treatment
Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies
Introduction To date, the transmission of Coronavirus Disease-2019 (COVID-19) is still
uncontrollable with the fact that the numbers of confirmed and death cases are still …
uncontrollable with the fact that the numbers of confirmed and death cases are still …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results
WHO Solidarity Trial Consortium - New England journal of …, 2021 - Mass Medical Soc
Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
[HTML][HTML] First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain
S Iftimie, AF López-Azcona, I Vallverdú… - PloS one, 2021 - journals.plos.org
Many countries have seen a two-wave pattern in reported cases of coronavirus disease-19
during the 2020 pandemic, with a first wave during spring followed by the current second …
during the 2020 pandemic, with a first wave during spring followed by the current second …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Drug treatments for covid-19: living systematic review and network meta-analysis
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
[HTML][HTML] Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis
Importance Convalescent plasma is a proposed treatment for COVID-19. Objective To
assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care …
assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …